Thermo Fisher Scientific TMO has entered into a Technology Alliance Agreement with the Chan Zuckerberg Institute for Advanced Biological Imaging (CZ Imaging Institute). The collaboration aims to develop new technologies to enable researchers to better visualize human cells, significantly boosting scientific research and discovery.

This project represents a crucial step toward the Chan Zuckerberg Initiative’s work to solve grand scientific challenges, including developing state-of-the-art imaging systems to observe human cells in extraordinary detail.

TMO Stock Outlook Following the News

After the announcement yesterday, TMO shares dropped by 0.4%, finishing the session at $511.68. On a promising note, the latest development will give a boost to the company’s EM business within the Analytical Instruments segment. Through a broader understanding of basic cellular biology, Thermo Fisher stands to benefit from the potential to unlock new layers of scientific research and therapeutic development, empowering researchers to uncover new insights in their labs. This collaboration with CZ Imaging Institute can help it create new approaches in analytical science that aid in future discoveries. Hence, we expect the news to positively boost market sentiment toward TMO stock.

Presently, Thermo Fisher boasts a market capitalization of $208.55 billion. The company’s earnings yield of 4.5% is well ahead of the industry’s -3.5% yield. It surpassed earnings estimates in each of the trailing four quarters, delivering an earnings surprise of 4.2%. 

More on Thermo Fisher’s New Tech Collaboration

Cryo-electron microscopy (cryo-EM) is an essential tool in disease research and creating lifesaving therapeutics, including vaccine development. As the technique advances, there is an increasing demand for greater contrast and higher resolution to see cellular structures in their native environments with more detail than ever. This includes the ability to analyze the inner workings of human cells in 3D and at industry-leading nanoscale resolution.

Image Source: Zacks Investment Research

In response, the respective teams are building on existing collaborations with leading researchers at the University of California, Berkeley and Lawrence Berkeley National Laboratory (Berkeley Lab), where the continuous laser phase plate for electron microscopy was invented and continues to be developed. Thermo Fisher will work alongside the CZ Imaging Institute to further develop laser phase plate technology for cryo-EM, enhancing cellular biology imaging at high resolution, while continuing the work with Berkeley Lab.

Industry Prospects Favoring Thermo Fisher

A research report estimates that the global cryo-EM market will reach $1.45 billion in 2025 and witness a compound annual rate of 11.9% through 2032. A key driver of the market’s growth in recent years has been the increasing focus on structural biology projects worldwide. Rising funding for cryo-EM from government and private organizations and technological advancements play a role.

More Updates From Thermo Fisher

This month, the company also unveiled the Vulcan Automated Lab, a cutting-edge solution designed to enhance productivity, increase yield and reduce operating costs for semiconductor manufacturers. Drawing on decades of electron microscopy (EM) innovation, the system represents a step change in atomic-scale data acquisition by integrating robotic handling with artificial intelligence (AI)-enhanced instruments for semiconductor analysis. 

TMO Stock Price Performance

In the past six months, TMO shares have fallen 17.4% compared with the industry’s 9.5% decline.

TMO’s Zacks Rank and Key Picks

Thermo Fisher currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space include Hims & Hers Health HIMS, Boston Scientific BSX and Cardinal Health CAH. Each of these carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Estimates for Hims & Hers Health’s 2025 earnings per share have jumped 12.5% to 63 cents in the past 30 days. Shares of the company have surged 106.3% in the past year against the industry’s 13.7% fall. Its earnings yield of 1.8% also outpaced the industry’s -6.7% yield. HIMS’ earnings surpassed estimates in two of the trailing four quarters, matched in one and missed on another occasion, the average surprise being 40.4%.

Boston Scientific shares have rallied 47.1% in the past year. Estimates for the company’s 2025 earnings per share have remained constant at $2.85 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 8.3%. In the last reported quarter, it posted an earnings surprise of 7.7%.

Estimates for Cardinal Health’s fiscal 2025 earnings per share have remained constant at $7.94 in the past 30 days. Shares of the company have jumped 22.2% in the past year against the industry’s 5% fall. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Boston Scientific Corporation (BSX) : Free Stock Analysis Report

Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report

Cardinal Health, Inc. (CAH) : Free Stock Analysis Report

Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research